Equal-WT
WhaleScore 2.0
?
LYNX1 CAPITAL MANAGEMENT LP
SAN JUAN PR
Investment Advisor
Hedge Fund
Lynx1 Capital Management is based out of San Juan. Lynx1 Capital Management is a hedge fund with 4 clients and discretionary assets under management (AUM) of $268,343,489 (Form ADV from 2024-08-07). Their last reported 13F filing for Q4 2024 included $266,711,190 in managed 13F securities
and a top 10 holdings concentration of 95.76%. Lynx1 Capital Management's largest holding is Merus N.V with shares held of 1,580,841. Whalewisdom has at least 15 13F filings, and 39 13G filings
Investment Strategy
The firm's investment strategies aim to generate attractive risk-adjusted returns over the long term. They primarily focus on biotechnology, leveraging deep fundamental research, scientific expertise, and extensive experience to identify long investments. The firm employs a long-only equity strategy, with the ability to enter into certain hedging transactions.
The firm's investment strategies also involve significant risks. The portfolio of investments is expected to be concentrated in the biotechnology industry, exposing the funds to the risk of adverse developments in or affecting this industry. The funds intend to hold a limited number of positions at any given time, potentially holding large positions in a few securities. This lack of diversification means that a significant loss in any one position could materially affect the net asset value and rate of return of the funds.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-12-31
Top Buys (13F)
| Name | % Change |
|---|---|
| CGEM Cullinan Therapeutic | 3.31% |
| KROS Keros Therapeutics, | 3.23% |
| GHRS GH Research PLC | 2.81% |
| ALLO Allogene Therapeutic | 2.53% |
| ALLK Allakos Inc | 1.65% |
2024-12-31
Top Sells (13F)
| Name | % Change |
|---|---|
| MRUS Merus N.V | 6.83% |
| CCCC C4 Therapeutics, Inc | 4.65% |
| KOD Kodiak Sciences Inc | 0.25% |
| PVLA Palvella Therapeutic | 0.22% |
| KNSA Kiniksa Pharmaceutic | 0.07% |
2024-12-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| MRUS Merus N.V | 24.92% |
| STOK Stoke Therapeutics I | 21.45% |
| GHRS GH Research PLC | 12.75% |
| CCCC C4 Therapeutics, Inc | 9.25% |
| ALLO Allogene Therapeutic | 8.68% |
2024-12-31
13F Activity
| Market Value | $267m, Prior: $282m |
| Inflows (Outflows) as % of Total MV | +12.7922% |
| New Purchases | 6 stocks |
| Added To | 5 stocks |
| Sold out of | 6 stocks |
| Reduced holdings in | 3 stocks |
| Top 10 Holdings % | 95.76% |
| Turnover %[1] | 50% |
| Turnover Alt %[2] | 4.75% |
| Time Held Top 20 | 3.3889 quarters |
| Time Held Top 10 | 4 quarters |
| Time Held All | 3.39 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-12-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-12-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-12-31